Novo Nordisk Investigational Site
Berlin, 14050, Germany
NCT Number: NCT01572753
This trial is conducted in Europe. The aim of the trial is to evaluate the optimal dosing conditions for semaglutide (a long acting GLP-1 analogue) in healthy male subjects.
Looking for future studies?
Notify Me18 year–55 year
Male
Interventional
Phase 1
Berlin, 14050, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
Time frame: 0-24hrs after the 10th dosing
Time frame: Post-dose at day 10
Time frame: Post-dose at day 10
Time frame: Post-dose at day 10
Novo Nordisk A/S
Industry
A Single Centre, Multiple Dose, Open Label Randomised Trial to Evaluate the Effect of Post Dose Meal Timings and the Effect of Volume of Water With Dosing on the Pharmacokinetic Properties of Oral Semaglutide in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01507285
Diabetes, Diabetes Mellitus
Manchester, United Kingdom
View Trial DetailsNCT01686945
Diabetes, Diabetes Mellitus
Berlin, Germany
View Trial DetailsNCT01037582
Diabetes, Diabetes Mellitus
Harrow, United Kingdom
View Trial DetailsNCT02016911
Diabetes, Diabetes Mellitus
Prague, Czechia
View Trial Details